Literature DB >> 12828064

Outcome of total pelvic exenteration for locally recurrent rectal cancer.

Hideyuki Ike1, Hiroshi Shimada, Shigeo Ohki, Shigeki Yamaguchi, Yasushi Ichikawa, Shouichi Fujii.   

Abstract

BACKGROUND/AIMS: Local recurrence occurs in 10 to 30% of patients with rectal cancer following curative resection. However treatment of choice remains controversial. We assessed the results of total pelvic exenteration for locally recurrent cancer of the rectum retrospectively.
METHODOLOGY: We reviewed medical charts of 45 patients with rectal cancer who underwent curative total pelvic exenteration for local recurrence. The cause of recurrence was classified into four groups: anastomotic, surgical cut-end, implantation, and lymphatic based on pathologic findings and computed tomography. Long-term survival was correlated with clinicopathologic variables.
RESULTS: Postoperative morbidity was 77.8% and in-hospital death occurred in 13.3% of patients. The overall 5-year survival rate was 14.1%. The 5-year survival rates stratified according to the expectation of curability were 31.6% for absolutely curative resection, 7.8% for relatively curative resection, and 0% for non-curative resection. Multivariate analysis revealed that the disease-free interval was the only independent prognostic factor. There was no benefit from perioperative radiation or intraoperative continuous pelvic peritoneal perfusion of the pelvis.
CONCLUSIONS: Total pelvic exenteration for local recurrence of rectal cancer can achieve long-term survival when curative resection is possible and the disease-free interval is long.

Entities:  

Mesh:

Year:  2003        PMID: 12828064

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  9 in total

1.  Total pelvic exenteration for rectal cancer: outcomes and prognostic factors.

Authors:  Trustin S Domes; Patrick H D Colquhoun; Brian Taylor; Jonathan I Izawa; Andrew A House; Patrick P W Luke; Jonathan I Izawa
Journal:  Can J Surg       Date:  2011-12       Impact factor: 2.089

2.  Effect of particle beam radiotherapy on locally recurrent rectal cancer: Three case reports.

Authors:  Yukako Mokutani; Hirofumi Yamamoto; Mamoru Uemura; Naotsugu Haraguchi; Hidekazu Takahashi; Junichi Nishimura; Taishi Hata; Ichiro Takemasa; Tsunekazu Mizushima; Yuichiro Doki; Masaki Mori
Journal:  Mol Clin Oncol       Date:  2015-03-30

3.  Pelvic exenteration for advanced and recurrent malignancy.

Authors:  Evita Zoucas; Sven Frederiksen; Marie-Louise Lydrup; Wiking Månsson; Pelle Gustafson; Per Alberius
Journal:  World J Surg       Date:  2010-09       Impact factor: 3.352

4.  Management of locally advanced primary and recurrent rectal cancer.

Authors:  Johannes H W de Wilt; Maarten Vermaas; Floris T J Ferenschild; Cornelis Verhoef
Journal:  Clin Colon Rectal Surg       Date:  2007-08

5.  Outcomes of pelvic exenteration for recurrent or primary locally advanced colorectal cancer.

Authors:  Hwa Yeon Yang; Sung Chan Park; Jong Hee Hyun; Ho Kyung Seo; Jae Hwan Oh
Journal:  Ann Surg Treat Res       Date:  2015-08-24       Impact factor: 1.859

6.  Pelvic Exenteration for Locally Advanced and Relapsed Pelvic Malignancies - An Analysis of 100 Cases.

Authors:  Nicolae Bacalbasa; Adina Croitoru; Irina Balescu; Mihaela Vilcu; Adrian Neacsu; Simona Dima; Iulian Brezean
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

Review 7.  [Multivisceral resection with and without HIPEC in cancer surgery].

Authors:  P Horvath; A Königsrainer
Journal:  Chirurg       Date:  2019-02       Impact factor: 0.955

8.  Retrospective review of pelvic malignancies undergoing total pelvic exenteration.

Authors:  Maureen P Kuhrt; Ravi J Chokshi; David Arrese; Edward W Martin
Journal:  World J Surg Oncol       Date:  2012-06-15       Impact factor: 2.754

9.  A Systematic Review on Overall Survival and Disease-Free Survival Following Total Pelvic Exenteration.

Authors:  Seyed Rouhollah Miri; Setareh Akhavan; Azam Sadat Mousavi; Seyedeh Razieh Hashemi; Shahrzad Sheikhhasan; Amir Almasi-Hashiani; Mohammad Sadegh Fakhari; Arezoo Esmailzadeh
Journal:  Asian Pac J Cancer Prev       Date:  2022-04-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.